JP2021535733A5 - - Google Patents
Info
- Publication number
- JP2021535733A5 JP2021535733A5 JP2020568955A JP2020568955A JP2021535733A5 JP 2021535733 A5 JP2021535733 A5 JP 2021535733A5 JP 2020568955 A JP2020568955 A JP 2020568955A JP 2020568955 A JP2020568955 A JP 2020568955A JP 2021535733 A5 JP2021535733 A5 JP 2021535733A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antigen
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024076402A JP2024105466A (ja) | 2018-06-13 | 2024-05-09 | Ｉｌ－１１抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1809699.0A GB201809699D0 (en) | 2018-06-13 | 2018-06-13 | IL-11 antibodies |
| GB1809699.0 | 2018-06-13 | ||
| PCT/EP2019/065598 WO2019238882A1 (en) | 2018-06-13 | 2019-06-13 | Il-11 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076402A Division JP2024105466A (ja) | 2018-06-13 | 2024-05-09 | Ｉｌ－１１抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021535733A JP2021535733A (ja) | 2021-12-23 |
| JP2021535733A5 true JP2021535733A5 (OSRAM) | 2022-06-20 |
Family
ID=63042160
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568955A Pending JP2021535733A (ja) | 2018-06-13 | 2019-06-13 | Ｉｌ−１１抗体 |
| JP2024076402A Pending JP2024105466A (ja) | 2018-06-13 | 2024-05-09 | Ｉｌ－１１抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076402A Pending JP2024105466A (ja) | 2018-06-13 | 2024-05-09 | Ｉｌ－１１抗体 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US11084874B2 (OSRAM) |
| EP (1) | EP3807314A1 (OSRAM) |
| JP (2) | JP2021535733A (OSRAM) |
| KR (1) | KR20210031690A (OSRAM) |
| CN (1) | CN113056481A (OSRAM) |
| AU (2) | AU2019286795B2 (OSRAM) |
| BR (1) | BR112020025443A2 (OSRAM) |
| CA (1) | CA3102483A1 (OSRAM) |
| CL (1) | CL2020003223A1 (OSRAM) |
| CO (1) | CO2020015383A2 (OSRAM) |
| CR (1) | CR20210009A (OSRAM) |
| DO (2) | DOP2020000245A (OSRAM) |
| EA (1) | EA202092668A1 (OSRAM) |
| EC (1) | ECSP21000695A (OSRAM) |
| GB (1) | GB201809699D0 (OSRAM) |
| IL (1) | IL279356A (OSRAM) |
| JO (1) | JOP20200309A1 (OSRAM) |
| MA (1) | MA52884A (OSRAM) |
| MX (1) | MX2020013583A (OSRAM) |
| PE (1) | PE20211498A1 (OSRAM) |
| PH (1) | PH12020552232A1 (OSRAM) |
| SA (1) | SA520420801B1 (OSRAM) |
| SG (1) | SG11202011782XA (OSRAM) |
| WO (1) | WO2019238882A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522186D0 (en) | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| CA3045871A1 (en) | 2016-12-16 | 2018-06-21 | Singapore Health Services Pte Ltd | Il-11 antibodies |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| US20200087390A1 (en) | 2016-12-21 | 2020-03-19 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| GB201716733D0 (en) * | 2017-10-12 | 2017-11-29 | Nat Univ Singapore | Treatment of SMC mediated disease |
| AU2020211695A1 (en) * | 2019-01-21 | 2021-09-02 | National University Of Singapore | Treatment of hepatotoxicity |
| GB201902419D0 (en) | 2019-02-22 | 2019-04-10 | Singapore Health Serv Pte Ltd | Treatment of kidney injury |
| CN114364693A (zh) | 2019-05-03 | 2022-04-15 | 新加坡保健服务私人有限公司 | 代谢性疾病的治疗和预防 |
| GB202009292D0 (en) | 2020-06-18 | 2020-08-05 | Singapore Health Serv Pte Ltd | Treatment and prevention of disease caused by type IV collagen dysfunction |
| US20230235029A1 (en) * | 2020-07-20 | 2023-07-27 | Integrated Biotherapeutics, Inc. | Broadly neutralizing binding molecules against marburgviruses |
| CN113651888B (zh) * | 2020-08-13 | 2022-08-16 | 广东东阳光药业有限公司 | Il-11的抗体及其应用 |
| GB202017244D0 (en) | 2020-10-30 | 2020-12-16 | Nat Univ Singapore | Methods to extend health-span and treat age-related diseases |
| CN114681592A (zh) * | 2020-12-31 | 2022-07-01 | 天境生物科技(杭州)有限公司 | 包含可溶性gp130二聚体的制剂和使用方法 |
| CN113980129B (zh) * | 2021-01-15 | 2023-07-28 | 东大生物技术(苏州)有限公司 | 一组il-11单克隆抗体及其医药用途 |
| CA3211686A1 (en) | 2021-02-26 | 2022-09-01 | Bayer Aktiengesellschaft | Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding |
| JP2024526944A (ja) | 2021-07-26 | 2024-07-19 | ベーリンガー・インゲルハイム・インターナショナル・ゲーエムベーハー | アルコール性肝疾患の処置および予防 |
| CN115975027B (zh) * | 2021-08-12 | 2023-10-20 | 广东东阳光药业股份有限公司 | Il-11人源化抗体及其应用 |
| WO2023034809A1 (en) | 2021-08-30 | 2023-03-09 | Lassen Therapeutics 1, Inc. | Anti-il-11rα antibodies |
| EP4448096A1 (en) | 2021-12-16 | 2024-10-23 | Singapore Health Services Pte. Ltd. | Treatment and prevention of glomerular disease |
| WO2023143556A1 (zh) * | 2022-01-29 | 2023-08-03 | 迈威(上海)生物科技股份有限公司 | 一种抗白介素-11的抗体及其应用 |
| GB202218388D0 (en) | 2022-12-07 | 2023-01-18 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| WO2024146458A1 (zh) | 2023-01-06 | 2024-07-11 | 广东东阳光药业股份有限公司 | 抗il-11细胞因子人源化抗体 |
| WO2024225979A1 (en) | 2023-04-25 | 2024-10-31 | Vvb Bio Pte Ltd | Anti il-11 antibody |
| CN120518762B (zh) * | 2023-06-05 | 2025-12-26 | 北京东方百泰生物科技股份有限公司 | 一种结合il-11的抗体、其抗原结合片段及应用 |
| GB202311050D0 (en) | 2023-07-19 | 2023-08-30 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| IL326237A (en) * | 2023-07-28 | 2026-03-01 | Mabwell Shanghai Bioscience Co Ltd | Use of anti-interleukin-11 antibody in the preparation of a drug for the treatment of tumors |
| WO2025108343A1 (zh) * | 2023-11-22 | 2025-05-30 | 上海华奥泰生物药业股份有限公司 | 靶向il-11的抗原结合蛋白 |
| WO2025146029A1 (zh) * | 2024-01-02 | 2025-07-10 | 上海华奥泰生物药业股份有限公司 | 靶向il-11和tslp的多特异性分子 |
| GB202405551D0 (en) | 2024-04-19 | 2024-06-05 | Vvb Bio Pte Ltd | Combination treatment |
| GB202408044D0 (en) | 2024-06-06 | 2024-07-24 | Vvb Bio Pte Ltd | gp130 antigen-binding molecules |
| WO2026001793A1 (zh) * | 2024-06-27 | 2026-01-02 | 上海华奥泰生物药业股份有限公司 | 靶向il-11的抗原结合蛋白及其用途 |
| CN119119262B (zh) * | 2024-08-02 | 2025-05-02 | 杭州曼迪生物科技有限公司 | 一种干细胞冻干粉及其在制备药物或者化妆品中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL356836A1 (en) * | 2000-02-10 | 2004-07-12 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
| US8518888B2 (en) * | 2008-10-14 | 2013-08-27 | Csl Limited | Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R |
| GB201522186D0 (en) * | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| RU2016125115A (ru) * | 2016-06-23 | 2017-12-28 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов |
| CA3045871A1 (en) * | 2016-12-16 | 2018-06-21 | Singapore Health Services Pte Ltd | Il-11 antibodies |
| RU2016151730A (ru) * | 2016-12-28 | 2018-06-29 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Антитела для лабораторной диагностики концентрации интерлейкина-11 |
-
2018
- 2018-06-13 GB GBGB1809699.0A patent/GB201809699D0/en not_active Ceased
-
2019
- 2019-06-13 EA EA202092668A patent/EA202092668A1/ru unknown
- 2019-06-13 SG SG11202011782XA patent/SG11202011782XA/en unknown
- 2019-06-13 CN CN201980054506.1A patent/CN113056481A/zh active Pending
- 2019-06-13 CA CA3102483A patent/CA3102483A1/en active Pending
- 2019-06-13 MA MA052884A patent/MA52884A/fr unknown
- 2019-06-13 CR CR20210009A patent/CR20210009A/es unknown
- 2019-06-13 US US16/440,840 patent/US11084874B2/en active Active
- 2019-06-13 AU AU2019286795A patent/AU2019286795B2/en active Active
- 2019-06-13 MX MX2020013583A patent/MX2020013583A/es unknown
- 2019-06-13 JP JP2020568955A patent/JP2021535733A/ja active Pending
- 2019-06-13 KR KR1020217000825A patent/KR20210031690A/ko not_active Ceased
- 2019-06-13 EP EP19734285.0A patent/EP3807314A1/en active Pending
- 2019-06-13 JO JOP/2020/0309A patent/JOP20200309A1/ar unknown
- 2019-06-13 BR BR112020025443-6A patent/BR112020025443A2/pt unknown
- 2019-06-13 PE PE2020001992A patent/PE20211498A1/es unknown
- 2019-06-13 WO PCT/EP2019/065598 patent/WO2019238882A1/en not_active Ceased
-
2020
- 2020-12-09 CO CONC2020/0015383A patent/CO2020015383A2/es unknown
- 2020-12-10 IL IL279356A patent/IL279356A/en unknown
- 2020-12-11 DO DO2020000245A patent/DOP2020000245A/es unknown
- 2020-12-11 CL CL2020003223A patent/CL2020003223A1/es unknown
- 2020-12-13 SA SA520420801A patent/SA520420801B1/ar unknown
- 2020-12-13 PH PH12020552232A patent/PH12020552232A1/en unknown
-
2021
- 2021-01-06 EC ECSENADI2021695A patent/ECSP21000695A/es unknown
- 2021-03-25 US US17/212,456 patent/US20210230266A1/en active Pending
-
2024
- 2024-03-01 US US18/592,746 patent/US20240270837A1/en active Pending
- 2024-03-01 US US18/592,665 patent/US20240190953A1/en active Pending
- 2024-05-09 JP JP2024076402A patent/JP2024105466A/ja active Pending
- 2024-10-29 DO DO2024000220A patent/DOP2024000220A/es unknown
-
2026
- 2026-03-05 AU AU2026201704A patent/AU2026201704A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260102485A1 (en) | Neutralizing anti-tl1a monoclonal antibodies | |
| JP5498018B2 (ja) | 胎盤成長因子（ＰｌＧＦ）媒介性の転移および／または血管新生の阻害 | |
| CN112703013B (zh) | Cd3抗原结合片段及其应用 | |
| JP2025028985A5 (OSRAM) | ||
| CN113056481A (zh) | Il-11抗体 | |
| JP2015214563A5 (OSRAM) | ||
| CN105358175B (zh) | 用于治疗硬皮病的抗ccl2和抗loxl2组合疗法 | |
| KR20150063447A (ko) | 알파-시누클레인을 인식하는 항체 | |
| CN104684931B (zh) | 抗cd26抗体及其用途 | |
| JP7231411B2 (ja) | 骨形成タンパク質６（ｂｍｐ６）の阻害剤を使用して疾患を処置する方法 | |
| JP2019530440A (ja) | インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物 | |
| JP2013165711A5 (OSRAM) | ||
| US11866513B2 (en) | Anti-TMPRSS6 antibodies and uses thereof | |
| TWI710575B (zh) | 人類抗-fgfr4抗體 | |
| Verma et al. | Inhibition of FLT1 ameliorates muscular dystrophy phenotype by increased vasculature in a mouse model of Duchenne muscular dystrophy | |
| US20220251177A1 (en) | Methods and compositions relating to anti-nucleolin recombinant immunoagents | |
| WO2025016063A1 (zh) | 可结合白介素31的抗体或其抗原结合片段及其制备方法和应用 | |
| JP2022512735A (ja) | 肝疾患を治療するための組成物および方法 | |
| EP2621948B1 (en) | Antibody specifically binding synovial microvasculature of arthritis patients | |
| JP2024531419A (ja) | 線維性疾患の治療におけるアルファ－エノラーゼアンタゴニストの使用 | |
| WO2025191002A1 (en) | Treatment and prevention of disease by il-7r inhibition | |
| US20200319166A1 (en) | Compositions and methods for detecting and treating pathological fibroblast cells | |
| US20260116990A1 (en) | Vhh antibodies and uses thereof | |
| JP2022524175A (ja) | Ｅｌｔｄ１に対するモノクローナル抗体及びその使用 | |
| JP2024531366A (ja) | 過体重及び肥満の個体におけるがんの治療のためのｇｐｒ６５標的化 |